SCHEMBL1000064

SCHEMBL1000064

Nc1c(Cl)cc(Br)cc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 11/20 0.42
ADRB1 P08588 1/20 0.42
KDM1A O60341 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
GLA P06280 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
TSHR P16473 1/20 0.33
IDO1 P14902 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31571901 1.00 ADRB2 (0.42) ADRB2ADRB1KDM1AALDH1A1CYP3A4
SCHEMBL31571902 1.00 ADRB2 (0.42) ADRB2ADRB1KDM1AALDH1A1CYP3A4
SCHEMBL9955892 0.80 ADRB2 (0.42) ADRB2KDM1ACYP3A4GLAPOLB
SCHEMBL2098677 0.79 CYP3A4 (0.36) ADRB2ADRB1ALDH1A1CYP3A4POLB
SCHEMBL10093727 0.79 ADRB2 (0.45) ADRB2ADRB1ALDH1A1CYP3A4GLA
SCHEMBL29470926 0.79 CYP3A4 (0.36) ADRB2ADRB1ALDH1A1CYP3A4POLB
SCHEMBL978692 0.78 NOTUM (0.42) KDM1AALDH1A1CYP3A4IDO1HTR3E
SCHEMBL3240959 0.78 ADRB2 (0.44) ADRB2ADRB1ALDH1A1CYP3A4GLA
SCHEMBL2434618 0.78 CYP3A4 (0.56) ADRB2ADRB1ALDH1A1CYP3A4GLA
SCHEMBL720822 0.78 KDM1A (0.38) ADRB2KDM1AALDH1A1GLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118026854-A Preparation method of 2-chloro-6-trifluoromethyl aniline 鹤壁市宝瑞德化工有限公司 2024-05-14 CN claimed
CN-113636919-B Method for synthesizing 3-chloro-5-trifluoromethyl trifluoroacetophenone 上海恩氟佳科技有限公司 2023-10-24 CN claimed
CN-113636919-A Method for synthesizing 3-chloro-5-trifluoromethyl trifluoro acetophenone 上海恩氟佳科技有限公司 2021-11-12 CN claimed
CN-119912402-A FTO inhibitor and preparation method and application thereof 中国科学院上海药物研究所 2025-05-02 CN disclosed
CN-118026854-A Preparation method of 2-chloro-6-trifluoromethyl aniline 鹤壁市宝瑞德化工有限公司 2024-05-14 CN disclosed
CN-118026854-A Preparation method of 2-chloro-6-trifluoromethyl aniline 鹤壁市宝瑞德化工有限公司 2024-05-14 CN disclosed
CN-113636919-B Method for synthesizing 3-chloro-5-trifluoromethyl trifluoroacetophenone 上海恩氟佳科技有限公司 2023-10-24 CN disclosed
CN-113636919-B Method for synthesizing 3-chloro-5-trifluoromethyl trifluoroacetophenone 上海恩氟佳科技有限公司 2023-10-24 CN disclosed
US-20230066771-A1 NUCLEAR RECEPTOR MODULATORS ABBVIE INC (US) 2023-03-02 US disclosed
CN-113636919-A Method for synthesizing 3-chloro-5-trifluoromethyl trifluoro acetophenone 上海恩氟佳科技有限公司 2021-11-12 CN disclosed
CN-113636919-A Method for synthesizing 3-chloro-5-trifluoromethyl trifluoro acetophenone 上海恩氟佳科技有限公司 2021-11-12 CN disclosed
EP-2183250-A1 NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS Valeant Pharmaceuticals International, Inc. (US) 2010-05-12 EP disclosed
US-20090170885-A1 NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) 2009-07-02 US disclosed
EP-2061465-A2 DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS Valeant Pharmaceuticals International (US) 2009-05-27 EP disclosed
WO-2009018466-A1 NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) 2009-02-05 WO disclosed
US-20080139610-A1 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2008-06-12 US disclosed
US-20080139610-A1 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2008-06-12 US disclosed
US-20080139610-A1 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators VALEANT PHARMACEUTICALS NORTH AMERICA (US) 2008-06-12 US disclosed
WO-2008024398-A2 DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2008-02-28 WO disclosed
WO-2008024398-A2 DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139610-A1 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators KCNQ2, KCNQ1, KCNQ5 ADRB2 1934/4885ADRB1 1277/4885KDM1A 165/4885
US-20090170885-A1 NAPHTHYRIDINE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS KCNJ11, KCNQ5, KCNJ1 ADRB2 627/4885ADRB1 415/4885KDM1A 1124/4885
US-20230066771-A1 NUCLEAR RECEPTOR MODULATORS NR1I2, NR1H2, NR5A2 ADRB2 87/4885ADRB1 48/4885KDM1A 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.